<DOC>
	<DOCNO>NCT02960022</DOCNO>
	<brief_summary>The purpose study collect long term safety data subject continue derive clinical benefit treatment Enzalutamide subject participation enzalutamide clinical study sponsor Astellas Medivation ( i.e. , parent study ) complete , minimum , primary analysis study specify evaluation period .</brief_summary>
	<brief_title>A Study Subjects With Prostate Cancer Who Previously Participated Enzalutamide Clinical Study</brief_title>
	<detailed_description>Subjects continue treatment regimen subject receive prior study . Dose change prior therapy subject receive previous protocol allow medical monitor approval . The day 1 visit study coincide last treatment visit study subject enrolling ( ≤ 7 day post last visit parent study ) . The subject follow accord local institution 's standard care require return institution every 12 week ( ± 7 day ) review adverse event ( AEs ) , collect concomitant medication , confirm discontinuation criterion meet , return dispense study drug receive study drug applicable . All AEs ( new ongoing study subject enrol ) Serious Adverse Events ( SAEs ) ( include death ) , collect time subject sign consent form end study visit .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Subject must currently receive enzalutamide prostate cancer study sponsor Astellas Medivation , base investigator 's assessment , benefit continue treatment . Subjects participate investigatorinitiated trial eligible . Subject able continue treatment regimen subject receive prior study . If investigator 's assessment , change need subject 's regimen ( e.g. , dose change Androgen deprivation therapy ( ADT ) drop combination therapy ) approval medical monitor require prior enrollment . Subject able swallow enzalutamide capsule comply study requirement . Subject female partner childbearing potential must continue use 2 form birth control , 1 must highly effective 1 must barrier method throughout study 3 month final enzalutamide administration . Subject agree avoid sperm donation study least 3 month final enzalutamide administration . Subject agree participate another interventional study treatment . Subject meet discontinuation criterion whose cancer progress current enzalutamide clinical study subject enrol . Subject require treatment plan use either following : New systemic therapy subject cancer ( palliative radiation therapy allow ) . The treatment agent administer previous study stop restart study represent new treatment . Investigational therapy enzalutamide . Subject currently participate investigatorinitiated interventional trial receive enzalutamide . Subject concurrent disease , infection , comorbid condition interferes ability subject participate study , place subject undue risk complicates interpretation data .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>prednisone</keyword>
	<keyword>MDV3100</keyword>
	<keyword>enzalutamide</keyword>
	<keyword>Xtandi</keyword>
	<keyword>abiraterone acetate</keyword>
</DOC>